GlassScriptPhysician profile
Jose Alberto Giron
NPI 1265619266
$12,166.22
in general payments reported to CMS, 2019-2025
28 companies · $867 in 2025
The $867 reported for 2025 was more than what 77% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,777 · 2020: $1,952 · 2021: $2,317 · 2022: $1,508 · 2023: $1,659 · 2024: $1,087 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,595 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,595.43 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $5,174.24 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $1,911.04 | 2019-2022 | |
| Janssen Biotech, INC. | $1,285.46 | 2019-2025 | Symtuza, Prezcobix, Tremfya |
| Abbvie INC. | $837.57 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $581.98 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Theratechnologies INC. | $534.91 | 2019-2023 | Trogarzo, Egrifta |
| Napo Pharmaceuticals INC | $344.85 | 2019-2025 | Mytesi |
| Janssen Products, LP | $331.99 | 2019-2022 | |
| Allergan, INC. | $276.63 | 2019 | |
| Paratek Pharmaceuticals, INC. | $221.13 | 2021 | |
| Emd Serono, INC. | $134.79 | 2019-2024 | Serostim, Serostim |
| Insmed, INC. | $114.30 | 2019-2025 | Brinsupri, Arikayce |
| Ucb, INC. | $70.32 | 2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $44.31 | 2020-2021 | |
| Novo Nordisk INC | $33.85 | 2023 | Rybelsus, Ozempic |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $30.93 | 2022 | |
| Janssen Scientific Affairs, LLC | $30.16 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.17 | 2025 | |
| Mylan Pharmaceuticals INC. | $25.71 | 2019 | |
| Romark Laboratories, Lc | $22.33 | 2020 | |
| Sobi, INC | $21.16 | 2025 | |
| Invivyd INC | $21.06 | 2025 | Pemgarda |
| Takeda Pharmaceuticals U.S.A., INC. | $20.01 | 2022 | |
| Tolmar, INC. | $18.24 | 2023 | |
| Vyera Pharmaceuticals, LLC | $17.30 | 2020 | |
| Aytu Biopharma, INC. | $15.06 | 2020 | |
| Glaxosmithkline, LLC. | $12.72 | 2019 | |
| Janssen Pharmaceuticals, INC | $8.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Giron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.